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Abstract: (1) Background: Knowledge about predictors for the long-time patency of recanalized
chronic total coronary occlusions (CTOs) is limited. Evidence from invasive follow-up in the absence
of acute coronary syndrome (routine surveillance coronary angiography) is scarce. (2) Methods: In a
monocentric-retrospective analysis, we obtained baseline as well as periprocedural data of patients
undergoing routine invasive follow-up. We defined target vessel failure (TVF) as a combined primary
endpoint, consisting of re-occlusion, restenosis, and target vessel revascularization (TVR). (3) Results:
We included 93 consecutive patients (15.1% female) from October 2013 to May 2018. After a follow-up
period of 206 ± 129 days (median 185 (IQR 127–237)), re-occlusion had occurred in 7.5%, restenosis in
11.8%, and TVR in 5.4%; the cumulative incidence of TVF was 15.1%. Reduced TIMI-flow immediately
after recanalization (OR for TVR: 11.0 (95% CI: 2.7–45.5), p = 0.001) as well as female gender (OR for
TVR: 11.0 (95% CI: 2.1–58.5), p = 0.005) were found to be predictive for pathological angiographic
findings at follow-up. Furthermore, higher blood values of high-sensitive troponin after successful
revascularization were associated with all endpoints. Interestingly, neither the J-CTO score nor the
presence of symptoms at the follow-up visit could be correlated to adverse angiographic results.
(4) Conclusions: In this medium-sized cohort of patients with surveillance coronary angiography, we
were able to identify reduced TIMI flow and female gender as the strongest predictors for future TVF.
Keywords: chronic total occlusion; target vessel failure; re-occlusion; surveillance
coronary angiography
1. Introduction
Coronary chronic total occlusion (CTO) is defined as either absent or minimal antegrade coronary
blood flow diagnosed by coronary angiography that had existed for >12 weeks [1]. According to
registry data, this distinct subtype of coronary artery disease has a prevalence of up to 20% of all
invasive coronary diagnostics [2]. Nevertheless, expert opinion on the optimal treatment strategy
(conservative, interventional, or surgical) is still controversial. According to contemporary data on
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clinical practice, only about one third of all patients with a CTO are treated by revascularization
(percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG)) [2].
In contrast to non-CTO PCIs with a procedural success rate of 98%, interventional CTO procedures
are more complex and have a significantly lower periprocedural revascularization rate of 60% to 70%
in non-specialized centers [2,3], which can exceed 90% in highly specialized units [4,5]. As a tool to
assess and grade lesion difficulty as well as predicting successful guidewire crossing within 30 min in
interventional recanalization, the J-CTO (Multicenter CTO Registry in Japan) score was developed
and validated. The presence of five specific lesion characteristics in CTO vessels that are known
to hamper revascularization success (blunt stump, occlusion length > 20 mm, calcification, vessel
bending > 45 degrees, and previously failed PCI) are assigned to one point each and summarized [6].
Vessel revascularization in CTO lesions has been associated with clinical improvement of angina and a
prognostic benefit regarding a lower rate of subsequent myocardial infarction and longer survival in
clinical registries [7–10]. However, evidence on long-term angiographic results as well as potential
predictors for vessel patency and re-occlusion post CTO-PCI is scarce. Results from other registries
imply that a higher pre-interventional J-CTO score—beyond acute success—might have an impact
on an increased probability for future adverse events [11,12]. Thus, the objectives of this study were
(i) to investigate the incidence of long-term target vessel failure (re-occlusion, restenosis, and target
vessel revascularization) as assessed by invasive follow-up in an all-comer retrospective monocentric
analysis, and (ii) to identify potential predictors of future target vessel failure after successful CTO
recanalization, including the J-CTO score.
2. Methods
Data of all patients consecutively treated with successful PCI for CTO-lesions in our center
between October 2013 to September 2017 that had an elective control coronary angiography until
May 2018 were included in this retrospective analysis. Surveillance angiography after a follow-up
period of 3 to 12 months was routinely recommended after successful recanalization of a CTO vessel
in accordance with the guidelines for high-risk lesions [13]. Patients primarily undergoing urgent
invasive control for acute coronary syndrome at a follow-up instead of the elective control coronary
angiography were excluded from the analysis. From October 2013 to September 2017, recanalization
of CTO lesions by PCI was successfully performed in 201 cases in our center. For this retrospective
analysis, data of 100 patients of this cohort with an invasive follow-up in our center were available
(49.8%). Seven patients were excluded because of either an extremely long latency from the index
procedure to follow-up (n = 3) and/or because of acute coronary syndrome as an indication for
repeated invasive coronary angiography (n = 5) in order to prevent potential bias by findings not
solely grounded on previously recommended routine control. All subjects were adult individuals (≥18
years) with pre-existing fluoroscopic evidence of a chronically occluded coronary vessel. The choice of
the interventional approach (antegrade vs. retrograde recanalization, radial or femoral access) and
material for intervention at the index visit (e.g., guiding catheters, guidewires, PCI balloons, and stents)
was subject to the discretion of the operator.
Patients’ characteristics, clinical features (angina pectoris: Defined as chest discomfort as classified
by Canadian Cardiovascular Society (CCS) class >2; symptoms: Defined as the presence of angina
pectoris CCS class >2 and/or dyspnea NYHA (New York Heart Association) class >1; echocardiographic
baseline parameters; proof of vitality of the region of the CTO), comorbidities, cardiovascular risk
factors, as well as features of the PCI procedure (e.g., treated vessel, dose of contrast dye and radiation,
fluoroscopy and procedural duration, J-CTO score and its subfactors (lesion entry, length, bending, and
previously failed PCI attempt) of the lesion, number and length of used stent material), periprocedural
levels of biomarkers (e.g., high-sensitive troponin I, creatinine, C-reactive protein), and clinical and
angiographic findings at the invasive follow-up visit were gathered and analyzed. For a detailed
protocol to quantify the J-CTO score, see [6]. Adipositas was defined as BMI (Body mass index)
≥ 30 kg/m2, according to the WHO definition. Renal impairment was defined as a glomerular
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filtration rate < 60 mL/min*1.73m2. The grade of a potential restenosis at the follow-up coronary
angiography was retrospectively reassessed and the diameter loss in comparison to the reference
vessel diameter was quantified in a semi-automatic manner by the Quantitative Coronary Analysis
(QCA) tool (Philips Healthcare, Andover, MA, USA) for this study. Additionally, TIMI flow—as
defined by the Thrombolysis in Myocardial Infarction Trial, quantified in Grades 0–3—was recorded
semi-quantitatively for the time points directly after the index procedure and at the follow-up visit.
The primary endpoints of the retrospective analysis of our patient cohort study were defined as
follows:
(1) Re-occlusion: Defined as TIMI flow grade 0, as assessed by fluoroscopy of the treated vessel at
the timepoint of surveillance coronary angiography.
(2) Restenosis: Defined as the recurrence of lumen loss >50% in the CTO vessel as quantified
retrospectively by QCA (including re-occlusion).
(3) Target vessel failure (TVF): Defined as a combined endpoint by the presence of re-occlusion,
restenosis, or target vessel revascularization (defined as a necessity for a repeated PCI within the
former CTO vessel).
We compared baseline parameters and values of clinical, fluoroscopic, and laboratory findings
during index hospitalization (CTO PCI procedure) and at the timepoint of invasive follow-up and
assigned patients to groups dependent on the presence of each singular endpoint as well as the
combined endpoint at the time of follow-up surveillance coronary angiography. Continuous variables
are presented as a mean ± standard deviation or as a median and interquartile range and categorial
variables are expressed as percentages. Continuous variables found not to follow a normal distribution
when tested with the modified Kolmogorov–Smirnov test (Lilliefors test) and Shapiro–Wilk-test were
compared using the Wilcoxon matched-pairs signed rank test or the Wilcoxon–Mann–Whitney test for
comparison between each two groups. Normally distributed continuous variables were compared
using the Students’ t-test and categorical variables with Fisher’s exact or Chi2 test, as appropriate.
Logistic regression analyses were performed in order to identify potential predictors for the
occurrence of endpoints. Odds ratios (ORs) are given with the corresponding 95% confidence intervals
(CIs). Logistic regressions were calculated by a univariate and a multivariate model, which was
adjusted for age, diabetes, hyperlipidemia, smoking, hypertension, and a positive family history
of cardiovascular disease. Receiver operating characteristics (ROCs) curves were calculated for the
sensitivity and specificity of the J-CTO score to predict each individual endpoint, and the areas under
the curve (AUC) are presented with the corresponding 95% CI. p values < 0.05 (two-sided) were
considered to be statistically significant. Statistical analysis was conducted using SPSS software version
24 (SPSS Inc., Chicago, IL, USA).
Since the study involved only an anonymized, retrospective analysis of diagnostic standard data,
ethics approval was not required according to German law.
3. Results
At the time of the index procedure, the 93 patients included in our analysis had a mean age of
65.6 ± 11.0 years old, 15.1% of them were female, and they had been symptomatic (angina or dyspnea)
before intervention in 81.7% of the cases. The predominant target vessel for CTO intervention was
the right coronary artery in 54.8% of the cases and the mean J-CTO score was 1.49 ± 1.09. Most
predominant cardiovascular risk factors comprised arterial hypertension (79.6%), smoking (57.0%),
and hyperlipidemia (59.1%) as well as a history of previous PCI (74.2%). A detailed overview of the
baseline characteristics of all included subjects is displayed in Table 1. A mean of 2.2 ± 1.1 stents were
implanted over an average lesion length of 56.6 ± 30.5 mm. One patient (1.1%) received treatment with a
drug-eluting balloon alone without additional stent implantation; in all other patients, second-generation
drug-eluting stents or scaffolds (in 76 cases (82.8%), everolimus-eluting stents (EESs); in 4 cases (4.3%),
biolimus eluting stents; in 9 cases (9.7%), everolimus-eluting bioresorbable vascular scaffolds (BVSs),
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and in 3 cases (3.2%), a combination of EESs and BVSs) were used to treat the lesion. No patient was
treated by POBA (plain old balloon angioplasty). Three patients (3.2%) encountered periinterventional
acute renal failure, and one patient (1.1%) had relevant bleeding at the site of vascular access; in all
other patients, no relevant major adverse events during the index visit were recorded. In total, 95.7% (n
= 89) of the recanalizations were performed via the antegrade approach and primary vascular access
was via the radial artery in 62.4% of cases (n = 58). In accordance with the guidelines [8], 89.2% (83
patients) were treated with dual anti-platelet therapy alone, and 10 cases (10.8%) with a combination of
antiplatelet therapy and an oral anticoagulant. The time elapsed from the index procedure to invasive
follow-up was, on average, 206 ± 129 days (median 185 (IQR 127–237 days)).
Table 1. Baseline characteristics (n = 93).
Parameter n (%) Mean ± SD Median (IQR)
Age at procedure (years) 65.6 ± 11.0 66.5 (58.2/74.6)
female gender 14 (15.1%)
Angina before intervention 53 (57.0%)
Symptoms before intervention 76 (81.7%)
multivessel disease 80 (86.0%)
previous CABG 10 (10.8%)
previous PCI 70 (74.2%)
Diabetes 31 (33.3%)
Smoking 53 (57.0%)
Hyperlipidemia 55 (59.1%)
Family history of CAD 24 (25.8%)
arterial hypertension 74 (79.6%)
peripheral artery disease 9 (9.7%)
cerebral artery disease 8 (8.6%)
renal insufficiency 6 (6.4%)
hyperthyroidism 13 (14.0%)
weight (KG) 90.2 ± 20.3 87.3 (78.0/100.8)
height (meters) 1.74 ± 0.10 1.76 (1.68/1.80)
Body mass index (kg/m2) 25.8 ± 4.8 24.9 (22.8/28.4)
Adipositas 14 (21.2%)
mean LVEF (%) 50.5 ±9.6 55.0 (45.0/55.0)
reduced LVEF at baseline 19 (29.7%)
proof of vitality of CTO region prior to
intervention 52 (57.8%)
CTO vessel
LAD 19 (20.4%)
LCX 23 (24.7%)
RCA 51 (54.8%)
J-CTO Score 1.49 ± 1.09 1.0 (1.0/2.0)
Components of the J-CTO Score
Entry 27 (29.0%)
Calcification 47 (50.5%)
Bending > 45◦ 25 (26.9%)
Lesion Length > 20 mm 29 (31.2%)
Retry Lesion 12 (12.9%)
Abbreviations: CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention, CTO: chronic total
occlusion, LVEF: left ventricular ejection fraction. LAD: left anterior descending artery, LCX: left circumflex artery,
RCA: right coronary artery. IQR: Interquartile Range, SD: standard deviation.
We compared patients’ clinical and periinterventional characteristics, including gender, coronary
vascular risk factors, renal impairment, left ventricular ejection fraction, duration and cumulative
fluoroscopy dose, stent length and number, periinterventional biomarkers, and symptoms, at baseline
and follow-up for each individual endpoint, and the cumulative endpoint. The incidence of re-occlusion
was low (7.5%, n = 7) and re-stenosis of the former CTO lesion (including re-occlusion) was observed
in 11.8% (n = 11). In five patients (5.4%), TVR was performed (two patients with treatment within the
former CTO lesion, in three patients with de novo stenosis adjacent to the former CTO lesion). Thus,
the incidence of the combined endpoint TVF was 15.1% (n = 14). Detailed results are presented in
Table 2 (for enhanced results, see Supplementary Materials Table S1).
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Table 2. Patients’ baseline, periprocedural, and follow-up characteristics stratified for endpoints.
Re-Occlusion Restenosis TVF
Re-Occlusion
(n = 7)
No
Re-Occlusion
(n = 86)
p-Value Restenosis(n = 11)
No Restenosis
(n = 82) p-Value TVF (n = 14)
No TVF
(n = 79) p-Value
Baseline parameters
female gender 28.6 14.0 0.283 36.4 12.2 0.058 35.7 11.3 0.034
Age at procedure 65.1 ± 6.9 65.6 ± 11.3 0.843 65.6 ± 7.5 65.6 ± 11.5 0.988 60.6 ± 13.4 66.5 ± 10.4 0.063
Reduced LVEF 20.0 30.5 1.000 22.2 30.9 0.713 30.0 29.6 1.000
LVEF baseline 51.8 ± 6.6 50.4 ± 9.8 0.923 51.0 ± 6.4 50.5 ± 10.0 0.667 50.4 ± 6.4 50.6 ± 10.1 0.466
Angina at baseline 57.1 57.0 1.000 54.5 57.3 1.000 50.0 58.2 0.574
Symptoms at baseline 100 80.2 0.342 100.0 79.3 0.206 92.9 79.7 0.453
Body Mass Index 23.6 ± 2.1 25.9 ± 4.9 0.356 23.1 ± 2.7 26.1 ± 4.9 0.130 23.8 ± 4.8 26.1 ± 4.8 0.158
J-CTO Score 1.86 ± 1.07 1.47 ± 1.09 0.307 1.55 ± 1.21 1.49 ± 1.08 0.843 1.60 ± 1.82 1.49 ± 1.05 0.889
J-CTO Score ≥ 3 28.6 22.1 0.654 37.5 22.0 0.707 28.6 21.5 0.511
Periprocedural characteristics
CTO vessel
- LAD 28.6 19.8
0.332
18.2 20.7
0.969
14.3 21.5
0.811- LCx 42.9 23.3 27.3 24.4 28.6 24.1
- RCA 28.6 57.0 54.5 54.9 57.1 54.40
Reduced TIMI-flow post intervention 100.0 8.1 <0.001 90.9 4.9 <0.001 71.4 5.1 <0.001
Stent length (mm) 36.3 ± 41.1 58.3 ± 29.2 0.044 38.2 ± 36.2 59.1 ± 29.0 0.020 43.0 ± 35.9 59.0 ± 29.0 0.042
Stent number 1.6 ± 1.6 2.2 ± 1.0 0.065 1.6 ± 1.4 2.2 ± 1.0 0.040 1.9 ± 1.3 2.2 ± 1.0 0.183
Fluoroscopy dose (cgy*dm) 8062 ± 4148 7363 ± 6308 0.351 7547 ± 4697 7398 ± 6352 0.677 7134 ± 4324 7465 ± 6449 0.830
Fluoroscopy time (min) 29.6 ± 18.0 26.0 ± 15.9 0.570 30.8 ± 18.8 25.7 ± 15.6 0.388 30.2 ± 18.0 25.6 ± 15.6 0.347
Duration (total) (min) 165.1 ± 26.8 123.8 ± 44.8 0.006 154.6 ± 44.0 123.2 ± 44.0 0.013 144.4 ± 45.7 123.8 ± 44.4 0.056
Contrast volume (mL) 277.4 ± 159.4 240.7 ± 103.1 0.662 279.2 ± 141.2 238.8 ± 102.4 0.372 263.8 ± 132.2 239.9 ± 103.2 0.576
Periinterventional CK (u/L) 178.3 ± 141.2 116.0 ± 94.9 0.276 132.7 ± 120.8 118.8 ± 96.6 0.929 123.5 ± 108.9 119.9 ± 98.9 0.802
High-sensitive Troponin I
periinterventional (pg/mL) 1126.3 ± 1560.6 412.0 ± 1391.4 0.013 771.4 ± 1255.7 420.7 ± 1425.5 0.013 662.4 ± 1124.7 425.5 ± 1451.3 0.044
Creatinine periinterventional (mg/dL) 0.93 ± 0.11 1.16 ± 0.97 0.412 0.96 ± 0.14 1.17 ± 0.99 0.636 0.96 ± 0.13 1.18 ± 1.01 0.580
CrP periinterventional (mg/L) 37.0 ± 59.5 7.77 ± 15.7 0.238 23.6 ± 47.7 8.1 ± 16.4 0.712 21.8 ± 45.6 8.1 ± 16.5 0.685
Symptoms at follow-up
Angina 28.6 32.5 1.000 36.4 31.6 0.741 35.7 31.6 0.763
Symptoms 42.9 53.4 0.704 54.5 52.4 1.000 50.0 53.2 1.000
values presented as percentages or mean values ± SD. Abbreviations: LVEF: left ventricular ejection fraction, CTO: chronic total occlusion, LAD: left anterior descending artery, LCx: left
circumflex artery, RCA: right coronary artery, CrP: c-reactive protein, CK: creatin kinase. TVF: Target Vessel Failure.
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When comparing baseline characteristics as well as periprocedural factors of the index procedure
of patients encountering endpoints to those without adverse outcomes at the time of follow-up, we
identified several parameters with statistically significant differences between the patient groups.
Patients with reduced TIMI flow of the target vessel directly at the end of the index procedure were
statistically significantly overrepresented in the groups encountering each of the endpoints. We
observed a significantly greater incidence of re-occlusion (100% vs. 8.1%, p < 0.001), restenosis (90.9%
vs. 4.9%, p < 0.001), and the combined endpoint (71.4% vs. 5.1%, p < 0.001). Furthermore, the patients
reaching the endpoints had higher periprocedural levels of high-sensitive troponin I (1126.3 ± 1560.6
vs. 412.0 ± 1391.4, p = 0.006 for re-occlusion, 771.4 ± 1255.7 vs. 420.7 ± 1425.5, p = 0.013 for restenosis,
and 662.4 ± 1124.7 vs. 425.5 ± 1451.3, p = 0.044 for TVF), and the cumulative length of implanted
stents was significantly shorter (36.3 ± 41.1 vs. 58.3 ± 29.2, p = 0.044 for re-occlusion, 38.2 ± 36.2 vs.
59.1 ± 29.0 mm, p = 0.020 for restenosis, 43.0 ± 35.9 vs. 59.0 ± 29.0 mm, p = 0.042 for TVF). Other
factors with statistically significant differences between the groups encountering endpoints were a
lower number of implanted stents for restenosis, as well as a longer cumulative duration of the CTO
index procedure both for re-occlusion and restenosis. Patients with female gender were significantly
overrepresented in the target vessel failure group at follow-up (35.7% vs. 11.3%, p = 0.034)—a similar
trend could also be observed for restenosis and re-occlusion, although this did not reach statistical
significance (for details, see Table 2).
We performed logistic regression analyses to assess the odds ratios of independent predictors for
each individual endpoint, including TVF, and adjusted those further for general cardiovascular risk
factors (age, diabetes, hyperlipidemia, smoking, hypertension, and family history of cardiovascular
disease) in a multivariate model. The results are presented in Table 3 (for further detailed calculations,
see online Supplementary Materials Table S1). Individual factors as potential predictors for TVF
comprised—as expected—reduced TIMI flow at the end of the index procedure all endpoints for
re-occlusion (OR: 20.36 (95% CI: 3.21–129.00), p = 0.001), restenosis (OR: 21.29 (95% CI: 4.28–105.97),
p < 0.01), and the combined endpoint/TVF (OR: 11.00 (95% CI: 2.66–45.45), p = 0.001). Female gender
proved to be a predictor for the occurrence of restenosis (OR: 8.88 (95% CI: 1.58–49.89), p = 0.013) as
well as target vessel failure (OR: 11.03 (95% CI: 2.08–58.47), p = 0.005). Of note, a lower BMI was
assessed to be predictive regarding the endpoints of restenosis (OR: 0.73 (95% CI: 0.55–0.98), p = 0.037)
and TVF (OR: 0.80 (95% CI: 0.65–0.99), p = 0.037).
The J-CTO score at the index procedure as well as the presence of its singular factors could not
be correlated with the later occurrence of any of the singular endpoints or TVF. Neither was there
any statistically significant difference between the groups reaching the endpoints and those without
adverse events, nor were any ORs statistically significant (Figure 1). In order to further determine
the sensitivity and specificity to predict each individual end point by the J-CTO score, we computed
ROC curves. The AUC for re-occlusion was calculated as 0.61 (95% CI 0.40–0.82), for restenosis as 0.52
(95% CI 0.32–0.71), and for TVF as 0.51 (95% CI 0.33–0.70) (see online Supplementary Materials Figure
S1), further documenting that the J-CTO score could not predict later adverse outcomes in our cohort.
Interestingly, the presence of typical angina pectoris and/or dyspnea at the time of follow-up did also
not have any correlation with the co-incidence of re-occlusion, restenosis, or TVR (see Table 2).
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Table 3. Multivariate regression analysis (odds ratios) for re-occlusion, restenosis, and TVF.
Re-Occlusion Restenosis TVF
OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
Baseline parameters
female gender 3.77 (0.54–26.43) 0.182 8.88 (1.58–49.89) 0.013 11.03 (2.08–58.47) 0.005
Age at procedure 0.99 (0.91–1.08) 0.822 1.00 (0.93–1.07) 0.995 0.95 (0.90–1.01) 0.080
Reduced LVEF 0.43 (0.04–5.09) 0.426 0.49 (0.08–3.10) 0.449 0.70 (0.13–3.87) 0.680
LVEF baseline 1,92 (0.91–1.16) 0.713 1.01 (0.92–1.10) 0.895 1.00 (0.92–1.09) 0.956
Angina at baseline 0.96 (0.19–4.79) 0.957 0.78 (0.20–2.97) 0.712 0.70 (0.21–2.40) 0.704
Symptoms at baseline not calculable not calculable 8.65 (0.62–121.31) 0.109
Body Mass Index 0.79 (0.57–1.09) 0.147 0.73 (0.55–0.98) 0.037 0.80 (0.65–0.99) 0.037
J-CTO-Score 1.42 (0.64–3.16) 0.394 1.03 (0.54–1.95) 0.929 1.11 (0.62–1.98) 0.728
J-CTO Score ≥ 3 1.40 (0.21–8.99) 0.721 1.26 (0.27–5.84) 0.768 1.35 (0.33–5.45) 0.676
Periprocedural characteristics
CTO vessel 0.50 (0.18–1.38) 0.180 0.98 (0.37–2.14) 0.797 0.97 (0.43–2.19) 0.936
-LAD
-LCx
-RCA
Reduced TIMI-flow post intervention 20.36 (3.21–129.00) 0.001 21.29 (4.28–105.97) <0.001 11.00 (2.66–45.45) 0.001
Stent length (mm) 0.97 (0.94–1.00) 0.081 0.98 (0.95–1.00) 0.051 0.98 (0.95–1.00) 0.060
Stent number 0.52 (0.21–1.29) 0.156 0.58 (0.28–1.17) 0.125 0.70 (0.38–1.29) 0.255
Fluoroscopy dose (cgy*dm) 1.00 (1.00–1.00) 0.748 1.00 (1.00–1.00) 0.871 1.00 (1.00–1.00) 0.868
Fluoroscopy time (min) 1.02 (0.97–1.07) 0.470 1.02 (0.99–1.07) 0.233 1.03 (0.99–1.06) 0.185
Duration (total) (min) 1.02 (1.00–1.04) 0.025 1.02 (1.00–1.03) 0.030 1.01 (1.00–1.03) 0.056
Contrast volume (mL) 1.00 (1.00–1.01) 0.287 1.00 (1.00–1.01) 0.200 1.00 (1.00–1.01) 0.486
Periinterventional CK (u/L) 1.01 (1.00–1.01) 0.153 1.00 (0.99–1.01) 0.757 1.00 (0.99–1.01) 0.973
High-sensitive Troponin I
periinterventional (pg/mL) 1.00 (1.00–1.00) 0.286 1.00 (1.00–1.00) 0.247 1.00 (1.00–1.00) 0.459
Creatinine periinterventional (mg/dL) 0.07 (0.00–8.94) 0.284 0.12 (0.00–4.57) 0.256 0.22 (0.01–5.91) 0.366
CrP periinterventional (mg/L) 1.03 (1.00–1.06) 0.049 1.02 (1.00–1.05) 0.067 1.02 (1.00–1.04) 0.103
Symptoms at follow-up
Angina 0.75 (0.13–4.45) 0.750 1.24 (0.30–5.07) 0.762 0.99 (0.28–3.59) 0.992
Symptoms 0.69 (0.14–3.36) 0.642 1.27 (0.34–4.71) 0.723 0.92 (0.28–3.01) 0.891
Abbreviations: LVEF: left ventricular ejection fraction, CTO: chronic total occlusion, LAD: left anterior descending artery, LCx: left circumflex artery, RCA: right coronary artery, CrP:
c-reactive protein, CK: creatin kinase. TVF: Target Vessel Failure.
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4. Discussion
Over the last years, percutaneous recanalization procedures of CTO lesions have been introduced
into daily clinical practice in most PCI centers. Successful intervention in CTO lesions has been
attributed to clinical as well as prognostic benefit [7–9]. Yet, follow-up data, including invasive control
coronary angiography, as well as evidence on potential predictors for long-term success are rare.
The key findings of this retrospective study are as follows: In a monocentric retrospective analysis
with routinely recommended invasive follow-up of intermediate to difficult CTO lesions (mean J-CTO
score 1.49 ± 1.09), re-occlusion rates tended to be low. Yet, the incidence of adverse findings, like
restenosis, target lesion revascularization, and the combined endpoint target vessel failure, was
moderate but still relevant. Of all clinical parameters entered in the analysis, reduced TIMI flow of
the target vessel at the end of the index procedure was the strongest predictor of the endpoints at the
follow-up visit. Furthermore, patients with higher periinterventional levels of high-sensitive troponin
I as well as a shorter cumulative length of implanted stents were overrepresented in the groups with
a later occurrence of adverse events at the timepoint of surveillance coronary angiography. Female
patients were at a higher risk for TVF. Interestingly, the pre-procedural J-CTO score was not predictive
of the occurrence of later restenosis, re-occlusion, or TLV in our cohort.
Other retrospective analyses have aimed to identify potential predictors for later cardiac adverse
events in cohorts of patients that underwent PCI for CTO lesions. In a retrospective analysis of 249
patients with a mean (non-invasive) follow-up of 19.8 ± 13.1 months, a higher J-CTO score was found
to be associated with a higher rate of major adverse cardiovascular events (MACEs) [11]. Although
the baseline characteristics in this cohort were mainly comparable (age 63 ± 11 years vs. 65.6 ±
11.0 years in our study, 70.3% vs. 84.9% male, right coronary artery as the target vessel in 49.4% vs.
54.8%, J-CTO score 1.8 ± 1.0 vs. 1.49 ± 1.09), the study design was distinctly different, which might
account for the controversial findings. The follow-up was also survey based without surveillance
coronary angiography and the endpoints were also determined differently by MACEs (cardiovascular
or unknown cause of death, myocardial infarction, TVR by PCI or CABG). In another large European
multi-center retrospective analysis of a total of 1395 patients with a mean follow-up of 23 months,
female sex, high J-CTO score ≥ 3, and prior PCI as well as reduced left ventricular function were found
to be correlated with a higher incidence of MACEs [12].
In our analysis, we identified female gender as a risk factor for TVF. Although some registries
generated evidence that women derive the same benefit from CTO-PCI as men in regard to clinical
benefit [14], female gender was found to be a predictor of PCI-related complications as well as MACEs
in other retrospective studies too [12,15,16]. The reason for this observation remains unclear but
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may include differences in the hormonal status between men and women. Yet, this finding might
strengthen the recommendation on optimal patient pre-selection. This should comprise of routine use
of non-invasive testing for myocardial ischemia prior to recanalization attempts, especially in female
patients who appear to be at elevated risk for future TVF.
Only a very few studies have assessed the mechanisms and predictors of target vessel failure in
CTO patients. In a prospective multicenter noninferiority trial comparing the use of a sirolimus-Eluting
stent (SES) to an Everolimus-eluting stent (EES) on 330 patients with total coronary occlusions, the
incidence of re-occlusion (2.2% in the SES vs. 1.4% in the EES group) and re-stenosis (8.0% vs. 2.1%)
was distinctly lower than in our study group [17]. The follow-up rate was high, with 85% in comparison
to nearly 50% in our study. Yet, a less strict definition of total coronary occlusion (estimated duration of
occlusion ≥ 4 weeks) was utilized for this trial, which might partially account for the different findings.
In a monocentric retrospective Korean registry on 235 patients with PCI for CTO with an invasive
follow-up rate of 61.3% after 6 months, a longer occlusion length was found to be predictive for a
higher incidence of TVR [16].
In our PCI center from which we recruited the study population, surveillance invasive follow-up
was routinely recommended but only opted for in nearly 50% of the individuals. According to
European Guidelines [13], follow-up coronary angiography might be routinely performed in high-risk
coronary setups. The strategy of routine invasive follow-up is discussed controversially because
of limited evidence and—in contrast to the situation in Europe—American guidelines abstain from
a recommendation [18]. One prospective randomized multicenter study in Japan ((Randomized
Evaluation of Routine Follow-up Coronary Angiography after Percutaneous Coronary Intervention
Trial) ReACT Trial) on 700 patients could not find evidence of a clinical benefit for a general angiographic
follow-up at least in a normal risk patient cohort [19]. Of course, it remains controversial whether
CTO-PCIs resemble a high-risk PCI collective (not further explained in the European guidelines) and,
furthermore, an impact on further clinical benefit by this strategy of an early invasive follow-up and
treatment of probably non-symptomatic re-stenosis remains hypothetic up to now. Nevertheless, our
study provides evidence that surveillance coronary angiography might be justified after recanalization
of CTO lesions, especially in the presence of specific factors predictive of TVF. Clinical findings, such
as ongoing symptoms alone, with definite exclusion of acute coronary syndrome, might not be helpful
to stratify patients at risk of potential TVF.
Some limitations of our study merit consideration: First, the design is a monocentric retrospective
analysis with a mid-term follow-up. Due to the observational nature of the study, the follow-up rate
was only 49.8%, which might further account for a potential selection bias, which has to be taken
into account in the interpretation of our results. BVS were used for treatment in some cases, which
are not available anymore. Although routine surveillance invasive follow-up was recommended
in all patients, symptomatic individuals could be overrepresented at the follow-up visit, as the
prevalence of angina pectoris and dyspnea at the time of follow-up was higher in comparison to other
registries [12]. Indication for TVR was based on individual assessment of the interventional operator
and not mandatorily grounded on further non-invasive or invasive evaluation of the stenosis (e.g.,
measurement of fractional flow reserve, intracoronary imaging like optical coherence tomography
or intravascular ultrasound) and a potential clinical and prognostic benefit of these interventions
has not been studied. Larger prospective randomized studies with defined protocol, including
intracoronary imaging or flow measurements, for surveillance coronary angiography would be
desirable. Furthermore, patients with female gender were relevantly underrepresented (15.1%), yet at
a comparable extent to most published CTO registries [11,12,14–16].
5. Conclusions
In this retrospective monocentric cohort of patients undergoing routine follow-up coronary
angiography after CTO recanalization, we found evidence that reduced TIMI flow at the end of
the index procedure as well as female gender could be predictors of later angiographic adverse
J. Clin. Med. 2020, 9, 178 10 of 11
outcome (TVF). Furthermore, patients with a shorter cumulative length of implanted stents and higher
periinterventional levels of high-sensitive troponin I were overrepresented in the group of patients
encountering re-occlusion, restenosis, and TVF at the timepoint of invasive follow-up. In contrast
to other registers, we could not prove any correlation between the initial J-CTO score of the treated
CTO lesion and the later occurrence of any of the endpoints. Remarkably, symptoms at the time of
follow-up coronary angiography could not be attributed to adverse angiographic results. Based on the
still relevant rate of TVF, even in populations of intermediate lesion complexity, such as ours, routine
invasive follow-up after CTO procedures appears to be justified and should rather be guided by the
presence of risk predictors, and not by the occurrence of angina (with the exception of acute coronary
syndrome). Thus, our present work might stress a potential beneficial value of routine surveillance
coronary angiography after CTO interventions, especially for females and patients with reduced TIMI
flow at the end of the index procedure.
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